S100A4 Antibody 0 Publications

Mouse Monoclonal| Catalog number: 66489-1-Ig |CloneNo.: 2G11B4

  • Print page
  • Download PDF

-_-

Freight/Packing

Con: 150 μg/150 μl

Choose size:

Please visit your regions distributor:


Species specificity:
Human, mouse

Positive WB detected in:
HeLa cells,A375 cells, A549 cells, PC-3 cells, NIH/3T3 cells

Positive IHC detected in:
human colon cancer tissue,human stomach cancer tissue, human tonsil tissue

Positive IF detected in:
HeLa cells

Recommended dilution:
WB : 1:1000-1:6000
IHC : 1:600-1:2400
IF : 1:50-1:500

Product Information


Source:
Mouse

Purification method:
Protein A purification

Isotype:
IgG2a

Storage:
PBS with 0.1% sodium azide and 50% glycerol pH 7.3. Store at -20oC. Aliquoting is unnecessary for -20oC storage.

Immunogen Information


Full name:
S100 calcium binding protein A4

Calculated molecular weight:
101aa,12 kDa

Observed molecular weight:
12 kDa

GenBank accession number:

Gene ID (NCBI):

Gene symbol
S100A4

Synonyms
18A2, 42A, Calvasculin, CAPL, FSP1, Metastasin, MTS1, P9KA, PEL98, Protein Mts1, Protein S100 A4, S100A4
Background

S100A4 is a member of the S100 family of calcium-binding proteins. The S100 family members have been involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100A4 is known to localize to and function in the nucleus, cytoplasm of cells, and the extracellular space. S100A4 has also been shown to be associated with tumor growth, motility, invasion, metastasis, angiogenesis, apoptosis, and chemoresistance. It is a fibroblast-specific protein associated with mesenchymal cell morphology and motility, is expressed during epithelial-mesenchymal transformations (EMT) in vivo (PMID: 9362334). It is a specific prognostic marker for renal survival in patients with IgAN (PMID: 16105038). It is also an improved marker for lung fibroblasts that could be useful for investigating the pathogenesis of pulmonary fibrosis(PMID: 15618458). Overexpression of S100A4 is correlated with a worse prognosis inpatients with various types of cancer.


Back
to top